

Lu-Wen Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8465916/publications.pdf>

Version: 2024-02-01

62
papers

755
citations

516561

16
h-index

677027

22
g-index

64
all docs

64
docs citations

64
times ranked

953
citing authors

#	ARTICLE	IF	CITATIONS
1	Childhood Cancer Drugs in China: An Overview and Comparison of Regulatory Approvals in China and the United States. <i>International Journal of Cancer</i> , 2022, 150, 482-490.	2.3	1
2	Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?. <i>Health Research Policy and Systems</i> , 2022, 20, 3.	1.1	11
3	Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China. <i>Frontiers in Pharmacology</i> , 2022, 13, 757398.	1.6	3
4	Study protocol for the evaluation of pharmacist-participated medication reconciliation at county hospitals in China: a multicentre, open-label, assessor-blinded, non-randomised, controlled study. <i>BMJ Open</i> , 2022, 12, e053741.	0.8	1
5	China starts to pay for pharmaceutical services. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1079-1080.	0.7	1
6	The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 256-266.	0.7	15
7	Impact of house price growth on mental health: Evidence from China. <i>SSM - Population Health</i> , 2021, 13, 100696.	1.3	9
8	Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis. <i>European Journal of Health Economics</i> , 2021, 22, 463-471.	1.4	20
9	Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending. <i>Cancer Communications</i> , 2021, 41, 345-348.	3.7	5
10	Risk of Liver Injury Associated with Intravenous Lipid Emulsions: A Prescription Sequence Symmetry Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 589091.	1.6	4
11	Differences of healthcare utilization and cost between cancer inpatients with and without depression: Based on national health insurance database. <i>Psycho-Oncology</i> , 2021, 30, 979-981.	1.0	2
12	Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. <i>Seminars in Oncology</i> , 2021, 48, 141-144.	0.8	14
13	Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 616453.	1.6	7
14	Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015-2018: A Retrospective Observational Study. <i>Frontiers in Pediatrics</i> , 2021, 9, 679203.	0.9	2
15	Outpatient prescribing pattern for acute bronchitis in primary healthcare settings in China. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 24.	1.1	8
16	Physician patient-sharing relationships and healthcare costs and utilization in China: social network analysis based on health insurance data. <i>Postgraduate Medicine</i> , 2021, 133, 798-806.	0.9	4
17	Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.5	7
18	Genetic variants of <i>PEAR1</i> and ischemic clinical outcomes in coronary artery disease patients: a systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2021, 22, 641-648.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Protocol of a tailored educational intervention for general practitioners on potentially inappropriate medications among older patients at community healthcare institutions in Beijing, China: a cluster-randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e046942.	0.8	0
20	The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. <i>BMJ Global Health</i> , 2021, 6, e006196.	2.0	29
21	Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 718086.	1.6	3
22	Antibiotic use and irrational antibiotic prescriptions in 66 primary healthcare institutions in Beijing City, China, 2015–2018. <i>BMC Health Services Research</i> , 2021, 21, 832.	0.9	7
23	Impact of temperature on morbidity: New evidence from China. <i>Journal of Environmental Economics and Management</i> , 2021, 109, 102495.	2.1	20
24	Outpatient Antibiotic Prescribing Patterns and Appropriateness for Children in Primary Healthcare Settings in Beijing City, China, 2017–2019. <i>Antibiotics</i> , 2021, 10, 1248.	1.5	10
25	Review of social networks of professionals in healthcare settings—where are we and what else is needed?. <i>Globalization and Health</i> , 2021, 17, 139.	2.4	6
26	The Impact of Physicians' Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 443-451.	1.0	1
27	Drug-Related Problems Identified During Pharmacy Intervention and Consultation: Implementation of an Intensive Care Unit Pharmaceutical Care Model. <i>Frontiers in Pharmacology</i> , 2020, 11, 571906.	1.6	8
28	Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015. <i>BMC Health Services Research</i> , 2020, 20, 654.	0.9	25
29	Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 5, 100060.	1.3	4
30	Differences in reimbursement listing of anticancer therapies in China: an observational study. <i>BMJ Open</i> , 2020, 10, e031203.	0.8	13
31	Potentially inappropriate medications among elderly patients in community healthcare institutions in Beijing, China. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 923-930.	0.9	10
32	Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017. <i>Frontiers in Pharmacology</i> , 2020, 11, 719.	1.6	14
33	The impact of the clinical pharmacist-led interventions in China: A systematic review and Meta-Analysis. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 366-377.	1.0	10
34	The impact of global budget on expenditure, service volume, and quality of care among patients with pneumonia in a secondary hospital in China: a retrospective study. <i>BMC Public Health</i> , 2020, 20, 522.	1.2	5
35	Secular trend analysis of antibiotic utilisation in China's hospitals 2011–2018, a retrospective analysis of procurement data. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 53.	1.5	19
36	Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	1

#	ARTICLE	IF	CITATIONS
37	Determinants of self-monitoring of blood glucose with type 2 diabetes based on 496 questionnaire surveys in China. <i>International Journal of Diabetes in Developing Countries</i> , 2019, 39, 181-187.	0.3	1
38	Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. <i>Advances in Therapy</i> , 2019, 36, 1114-1125.	1.3	18
39	How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2199-2205.	1.6	14
40	Effect of physicians' knowledge on antibiotics rational use in China's county hospitals. <i>Social Science and Medicine</i> , 2019, 224, 149-155.	1.8	22
41	Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. <i>BMJ Open</i> , 2019, 9, e031658.	0.8	17
42	<p>Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database<p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1057-1065.	1.5	15
43	Burden of visual impairment associated with eye diseases: exploratory survey of 298 Chinese patients. <i>BMJ Open</i> , 2019, 9, e030561.	0.8	8
44	Assesment of Adulterated Traditional Chinese Medicines in China: 2003-2017. <i>Frontiers in Pharmacology</i> , 2019, 10, 1446.	1.6	29
45	Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 459.	0.9	9
46	Optimising early nutritional support for medical inpatients. <i>Lancet, The</i> , 2019, 394, 2069-2070.	6.3	0
47	Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1262-1279.	2.2	44
48	The effect of the implementation of low price medicine policy on medicine price in China: A retrospective study. <i>International Journal of Health Planning and Management</i> , 2018, 33, e798.	0.7	6
49	Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. <i>Journal of Infection and Public Health</i> , 2018, 11, 339-346.	1.9	18
50	A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals. <i>International Journal for Equity in Health</i> , 2018, 17, 158.	1.5	22
51	Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China. <i>BMJ Open</i> , 2018, 8, e022328.	0.8	14
52	Trends and patterns of antibiotic consumption in China's tertiary hospitals: Based on a 5 year surveillance with sales records, 2011-2015. <i>PLoS ONE</i> , 2017, 12, e0190314.	1.1	42
53	Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China. <i>Chinese Medical Journal</i> , 2016, 129, 1387-1393.	0.9	8
54	Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 74.	1.2	18

#	ARTICLE	IF	CITATIONS
55	Methods for using microblogs for health communication with a pharmacist-based account. <i>Patient Education and Counseling</i> , 2016, 99, 1432-1437.	1.0	0
56	Traditional Chinese patent medicines for cancer treatment in China: a nationwide medical insurance data analysis. <i>Oncotarget</i> , 2015, 6, 38283-38295.	0.8	32
57	Rapid Determination of Bile Acids in Bile from Various Mammals by Reversed-Phase Ultra-Fast Liquid Chromatography. <i>Journal of Chromatographic Science</i> , 2015, 53, 1060-1065.	0.7	8
58	Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 1319-1324.	0.4	24
59	Effect of critical care pharmacist's intervention on medication errors: A systematic review and meta-analysis of observational studies. <i>Journal of Critical Care</i> , 2015, 30, 1101-1106.	1.0	53
60	TRIPS-plus and access to medicines in China. <i>Journal of Public Health Policy</i> , 2013, 34, 226-238.	1.0	4
61	Can Price Controls Reduce Pharmaceutical Expenses? A Case Study of Antibacterial Expenditures in 12 Chinese Hospitals from 1996 to 2005. <i>International Journal of Health Services</i> , 2013, 43, 91-103.	1.2	21
62	The Impact of Sanming Healthcare Reform on Antibiotic Appropriate Use in County Hospitals in China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5